Analysis of hormonal therapy for advanced metastatic prostate cancer
10.3760/cma.j.issn.1000-6702.2009.12.017
- VernacularTitle:晚期转移性前列腺癌内分泌治疗分析
- Author:
Chunguang MA
;
Dingwei YE
;
Xudong YAO
;
Shilin ZHANG
;
Bo DAI
;
Hailiang ZHANG
;
Yao ZHU
;
Yijun SHEN
;
Yiping ZHU
;
Guohai SHI
;
Xiaojian QIN
;
Guowen LIN
;
Lifeng YANG
;
Boshuai YANG
;
Wenjun XIAO
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Hormonal therapy;
Prognosis
- From:
Chinese Journal of Urology
2009;30(12):831-833
- CountryChina
- Language:Chinese
-
Abstract:
Objective To find the predictive factors that related to the effect of hormonal therapy and the survival of advanced metastatic prostate cancer. Methods Three hundred and Sixty-four cases of metastatic prostate cancer were treated with hormonal therapy in Cancer Hospital Fudan University in Shanghai from December 1996 to March 2008. The patients were followed up to the 31 March 2008 and the median follow-up time was 24 months. Two hundred and fifty cases have progressed into the stage of hormonal independent. The statistic software used in this study was SPSS 15. 0. Cumulative survival was analyzed by Kaplan-Meier method. Cox regression was used for univa-riate and multivariate analysis. Log-rank method was used for the significance test. The statistical difference was accepted when the P-value was lower than 0. 05. Results The effective rate of hormonal therapy for advanced metastatic prostate cancer was 98%. The median time of progression free survival of hormonal therapy was 20 months, and the one-year, two-year, three-year progression free survival rate was 69%, 39%, 27%, respectively. The survival analysis indicated that baseline PSA level more than 20ng/ml, with visceral organ metastasis, the PSA nadir more than Ing/ml during hormonal therapy, the time from the start of hormonal therapy to the PSA nadir less than 5 months were poor prognostic factors of progression free survival. Conclusions The baseline PSA level, clinicalstage, the PSA nadir during hormonal therapy and the time form the start of hormonal therapy to the PSA nadir could be the factors that predict the progression free survival time during hormonal therapy.
